Scientists at the Icahn School of Medicine at Mount Sinai have developed an experimental immunotherapy that takes an ...
Universal gene‑edited CAR‑T therapies turn donor T cells into off‑the‑shelf cancer treatments, cutting delays and costs while ...
The Food and Drug Administration (FDA) has approved Breyanzi ® (lisocabtagene maraleucel; liso-cel) for the treatment of adult patients with relapsed or refractory (R/R) marginal zone lymphoma (MZL) ...
The FDA's breakthrough therapy designation facilitates accelerated development and regulatory review for therapies showing ...
Cipla has partnered with ImmunoACT to introduce the CAR-T cell therapy 'talicabtagene autoleucel' in South Africa, Algeria, ...
Wugen, Inc., a clinical-stage biotechnology company developing allogeneic, off-the-shelf cell therapies for the treatment of ...
Cipla partners with ImmunoAct to introduce India’s first CAR-T cell therapy in Africa, enhancing accessible cancer treatment ...
Early phase 1 data suggest that in vivo, off-the-shelf CAR T therapy may be feasible in multiple myeloma, offering the promise of faster, less toxic treatment without lymphodepletion while raising ...
Treatment with nivolumab (Opdivo) had limited benefit in patients with multiple myeloma (MM) or non-Hodkin lymphoma (NHL) ...
Cipla partners with ImmunoACT to commercialise CAR-T cell therapy in South Africa, Algeria, and Morocco. Expanding access to innovative cancer treatment.
Cipla Limited partners with ImmunoACT to launch talicabtagene autoleucel CAR-T therapy for blood cancers in South Africa, ...
AstraZeneca had already bagged the rights to the AbelZeta Pharma-partnered CAR-T cell therapy for most of the world. | The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback